Search clinical trials for: PD-L1 Monoclonal Antibody Combined With Lenalidomide

Total 541 results

LiNing

Not yet recruiting

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Colorectal Neoplasms

China
Dragonboat Biopharmaceutical Company Limited
West China Hospital

Recruiting

An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Lymphoma | Tumor, Solid

China
Shanghai Zhongshan Hospital

Recruiting

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Cholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4

China
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Shanghai Zhongshan Hospital

Recruiting

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

Oesophageal Squamous Cell Carcinoma

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Carcinoma | Solid Tumor

China
Lee's Pharmaceutical Limited

Not yet recruiting

Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

High-grade Osteosarcoma
Changhai Hospital

Not yet recruiting

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody (PMMR/MSS)

Rectal Cancer
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Advanced Lung Carcinoma
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC

Safety Issues | Effect Increased
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Dragonboat Biopharmaceutical Company Limited
Fudan University

Recruiting

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

Bladder Cancer | Renal Carcinoma | Advanced Penile Carcinoma

China
Ruijin Hospital

Not yet recruiting

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma (ENKTL)

NK-T-Cell Lymphoma, Extranodal

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Lee's Pharmaceutical Limited

Recruiting

Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Lee's Pharmaceutical Limited

Enrolling by invitation

A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

Biliary Tract Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Leiden University Medical Center
Radboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaborators

Active, not recruiting

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)

Uterine Neoplasms | Endometrial Neoplasms | Endometrium Cancer

Netherlands
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shandong Cancer Hospital and Institute

Recruiting

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Colorectal Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Squamous Cell Cancer of Head and Neck

China
Zhejiang University

Recruiting

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Megan Daly, MD
National Cancer Institute (NCI); Genentech, Inc.

Terminated

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Shanghai Chest Hospital

Recruiting

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI); Imugene Limited

Active, not recruiting

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Megan Daly, MD
EMD Serono

Completed

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Metastatic Non-small Cell Lung Cancer (NSCLC)

United States
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Osteosarcoma

China
Genentech, Inc.

Completed

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain, Belgium, Korea, Republic of, Canada, Australia, France
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
University of Colorado, Denver
AstraZeneca

Withdrawn

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Pancreatic Cancer

United States
Fudan University

Recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Shen Lin
NeoCura

Not yet recruiting

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer

Gastric Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases

Colorectal Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Uterine Cervical Cancer

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Cervical Cancer

China
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)

Carcinoma | Solid Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
Xiaorong Dong

Unknown

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

NSCLC | Anlotinib | PD-1/L1 Inhibitor
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Shanghai Jiao Tong University Affiliated Sixth...

Recruiting

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer (PD-1)

Cervical Cancer | Radiotherapy | Neoadjuvant Chemotherapy | PD-1 Antibody

China

3

Subscribe